ChinaDrugStatus

Tazemetostat hydrobromide

氢溴酸他泽司他
Brand: Tazverik / 达唯珂·Oncology / Hematology·Last verified 2026-11-20

EZH2 inhibitor listed in the 2025 Commercial List (#16) for EZH2-mutated r/r follicular lymphoma; not carried into the 2026 Commercial List or 2026 NRDL.

China Approval (NMPA)

Pending Verification

Reimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.

Verify directly on NMPA Portal ↗

National Reimbursement

Not Listed

Not included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).

Commercial Insurance List

2025 Only (Not in 2026)

Previously listed in the 2025 Commercial Insurance Innovative Drug List (#16). Omitted from the 2026 Commercial List edition.

Approved Products, Dosage Forms & Approval Numbers

0 verified NMPA records
Individual NMPA approval numbers (国药准字) and dosage strength rows have not yet been manually backfilled for this drug in our launch sample. Check the NMPA Drug Database Portal ↗ or request priority backfill.

Change Timeline

  1. (2026-01-01)Commercial List· Catalog published: Dec 7, 2025

    2025 Commercial List · Removed in 2026 Edition (#16)

    Monotherapy for adult EZH2-mutation-positive r/r follicular lymphoma after ≥2 prior systemic therapies (listed in 2025 Commercial List #16; omitted from 2026 edition).

    Chinese original: 单药用于既往接受过至少两种系统性治疗后的EZH2突变阳性复发或难治性滤泡性淋巴瘤(FL)成人患者。

    NHSA · PDF p.4Verified 2026-11-20

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

氢溴酸他泽司他片dosage name(NHSA)
Tazverikbrand en(WHO)
达唯珂brand zh(NHSA)

Primary Sources for This Record